Scholarlink

<p>SLC7A14 is a putative amino acid transporter whose physiological role remains poorly characterized, despite its association with retinal degeneration, auditory defects, and metabolic dysfunctions. Confocal microscopy was performed in HEK293 transiently transfected with the human SLC7A14 (hSLC7A14), demonstrating a lysosomal localization, as previously suggested. To carry on functional and kinetic characterization, the protein was overexpressed in <i>E. coli</i>, and purified from insoluble fraction through affinity chromatography followed by SEC with a yield of 156&#xa0;mg/L of bacterial cell culture. The homogeneous hSLC7A14 showed an apparent molecular mass of 72&#xa0;kDa on SDS-PAGE and was reconstituted into proteoliposomes for functional assays. hSLC7A14 showed high specificity towards arginine, not histidine or glutamine, with a measured Km of 1.2 ± 0.21&#xa0;mM. The arginine transport was inhibited by cysteine and threonine, but not by other amino acids or GABA. Inhibition kinetics identified metformin as an inhibitor of the transporter showing a mixed type of inhibition with a measured Ki in the same order of that of arginine. These findings are in agreement with hSLC7A14 being a specific lysosomal arginine transporter, with potential involvement in the mTORC1 signalling. The described results represent a first step to further elucidate hSLC7A14 role in human physiology and disease. Moreover, the identification of experimental conditions for measuring specific transport activity will allow screening of ligands as inhibitors or functional modulators opening perspectives for structure/function relationship studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characterization of the lysosomal arginine transporter SLC7A14

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月26日

查看全文
  • Deborah Giudice,
  • Francesca Barone,
  • Tiziano Mazza,
  • Mariafrancesca Scalise,
  • Lara Console,
  • Cesare Indiveri

摘要

SLC7A14 is a putative amino acid transporter whose physiological role remains poorly characterized, despite its association with retinal degeneration, auditory defects, and metabolic dysfunctions. Confocal microscopy was performed in HEK293 transiently transfected with the human SLC7A14 (hSLC7A14), demonstrating a lysosomal localization, as previously suggested. To carry on functional and kinetic characterization, the protein was overexpressed in E. coli, and purified from insoluble fraction through affinity chromatography followed by SEC with a yield of 156 mg/L of bacterial cell culture. The homogeneous hSLC7A14 showed an apparent molecular mass of 72 kDa on SDS-PAGE and was reconstituted into proteoliposomes for functional assays. hSLC7A14 showed high specificity towards arginine, not histidine or glutamine, with a measured Km of 1.2 ± 0.21 mM. The arginine transport was inhibited by cysteine and threonine, but not by other amino acids or GABA. Inhibition kinetics identified metformin as an inhibitor of the transporter showing a mixed type of inhibition with a measured Ki in the same order of that of arginine. These findings are in agreement with hSLC7A14 being a specific lysosomal arginine transporter, with potential involvement in the mTORC1 signalling. The described results represent a first step to further elucidate hSLC7A14 role in human physiology and disease. Moreover, the identification of experimental conditions for measuring specific transport activity will allow screening of ligands as inhibitors or functional modulators opening perspectives for structure/function relationship studies.